
Clinical development is more than a single protocol or trial. It is the strategic process of determining what evidence a product needs, when that evidence should be generated, and how each study contributes to the overall development program.
Dynamill Research provides clinical development services and clinical development consulting for medical device, diagnostic, IVD, digital health, and AI-enabled healthcare companies.
We help sponsors turn product objectives into practical clinical development strategies, evidence roadmaps, study sequences, milestones, and decision points—creating a clearer path from early development through pivotal evidence and post-market planning.
A clinical study should never exist in isolation. Every study should answer a defined development question and contribute evidence that moves the product toward its next milestone.
Dynamill works with sponsors to establish a clinical development framework that considers:
Our goal is to help sponsors understand what needs to happen next and why.
A strong program begins with a clear clinical development strategy.
Dynamill helps sponsors define the role clinical evidence will play across the product lifecycle and determine how individual studies should contribute to the broader development objective.
Our support may include:
Instead of approaching each study as a separate project, we help sponsors build a connected clinical program.
Not every evidence question needs to be answered at the same time.
An effective clinical evidence strategy identifies which questions should be addressed early, which require formal clinical investigation, and which may be better answered later through additional or real-world evidence.
Dynamill helps sponsors map:
Current Evidence → Evidence Gaps → Required Studies → Development Milestones → Future Evidence Needs
This roadmap can help teams prioritize resources, reduce unnecessary work, and make development decisions with greater clarity.
Clinical development involves multiple interconnected activities and stakeholders.
Dynamill helps sponsors create an integrated development plan that brings these components into one coordinated framework.
Program planning may consider:
This creates visibility beyond the next study and helps teams understand how today's decisions may influence later development stages.
Running the right study at the wrong time can create unnecessary cost, delay, or duplicated effort.
Dynamill helps sponsors determine how studies should be sequenced based on the questions the development program needs to answer.
Depending on the product, this may involve planning the progression from:
Early Evidence → Feasibility → Validation → Pivotal Evidence → Market Introduction → Post-Market Evidence
Clear sequencing helps sponsors establish logical development milestones and determine what evidence is needed before moving to the next stage.
Development delays often begin as small unresolved dependencies.
A missing evidence requirement, an unrealistic milestone, an unclear ownership structure, or a late cross-functional decision can eventually affect the entire program.
Dynamill incorporates development risk planning into clinical strategy by helping teams identify:
The objective is not simply to document risk—but to identify it early enough to influence the development plan.
As development programs become more complex, sponsors need clear visibility into decisions, priorities, responsibilities, and emerging risks.
Dynamill supports clinical program management and governance through structured oversight designed to keep development activities connected to the broader program objective.
This may include:
Good governance helps keep teams aligned around what matters most rather than simply tracking activity.
Clinical development sits at the intersection of multiple functions.
Clinical, regulatory, scientific, data, quality, laboratory, operational, and commercial teams may all influence the evidence a product ultimately needs.
Dynamill helps sponsors create stronger alignment across these functions so development decisions are made with the full evidence pathway in view.
Early alignment can help reduce:
For detailed FDA regulatory strategy and submission planning, sponsors can also explore Dynamill Regulatory Consulting & FDA Submission Support.
Clarify the product, development stage, clinical objectives, existing evidence, and future milestones.
Determine the most important evidence gaps, development dependencies, and unanswered clinical questions.
Build a clinical development roadmap showing studies, evidence requirements, milestones, and decision points.
Sequence development activities according to evidence value, timing, risk, and program priorities.
Connect clinical, regulatory, scientific, operational, and organizational stakeholders around one development plan.
Use emerging evidence and development milestones to guide the program toward the next decision.
Development-Level Thinking
We look beyond the next study and consider how each evidence-generating activity contributes to the overall development program.
Diagnostics & Device Expertise
Our focus on diagnostics, IVDs, medical devices, and emerging healthcare technologies helps us understand development challenges that may differ from traditional pharmaceutical programs.
Senior-Level
Engagement
Sponsors work with experienced professionals who remain close to the strategy, decisions, risks, and development objectives.
Lean, High-Touch
Model
Fewer layers mean clearer ownership, faster communication, and more direct access to the people supporting your program.
Strategy Connected to Execution
When the program moves from planning into clinical execution, Dynamill’s CRO capabilities allow strategic objectives to remain connected to operational realities.
Regulatory
Awareness
Clinical development decisions are considered in the context of future evidence and regulatory requirements without treating regulatory planning as a separate, late-stage activity.
Dynamill supports sponsors through complementary service areas:
Clinical Development
What evidence is needed, when should it be generated, and how should the development program progress?
Diagnostics & IVD Services
How should specialized diagnostic and medical device clinical studies be designed and executed?
Regulatory Consulting & FDA Support
How should the evidence and development program align with FDA strategy and submission requirements?
Together, these capabilities help sponsors move from development strategy to clinical evidence to regulatory readiness with greater continuity.
Clinical development services help healthcare product companies plan how clinical evidence will be generated across the development lifecycle. This can include evidence strategy, clinical development planning, study sequencing, milestone planning, risk assessment, program governance, and lifecycle evidence planning.
A clinical development strategy defines the clinical questions a development program must answer and establishes how studies and other evidence-generating activities will address those questions over time.
A clinical development roadmap connects current evidence, evidence gaps, planned studies, development milestones, and future evidence requirements into one structured plan.
Clinical development planning should ideally begin before individual studies are finalized. Early planning allows sponsors to understand how each study fits into the broader evidence and development strategy.
Clinical Development focuses on the overall evidence strategy, development roadmap, study sequence, milestones, and program-level decisions.
Diagnostics & IVD Services focuses on the specialized design and operational execution of diagnostic, IVD, and medical device clinical studies.
Clinical Development determines how the clinical evidence program should progress. Regulatory Consulting focuses on regulatory pathway strategy, FDA interactions, evidence requirements, and submission readiness.The two functions should remain aligned throughout development.
You're about to visit an external website. Do you wish to continue?